Inomata et al. reported that when bone metastases worsen in patients with EGFR‐positive NSCLC during EGFR–TKI treatment, the effect of the addition of radiotherapy while continuing EGFR–TKI results in PFS after relapse is comparable to that of subsequent chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.